The integration of immune cell engineering, including chimeric antigen receptor therapy (CAR-T) and TCR-therapies targeting CRC-associated antigens like CEA, represents another promising frontier, albeit one with challenges related to toxicity and limited efficacy in solid tumors [161]. Here, CEACAM5 is linked to colorectal carcinoma.